STOCK TITAN

Instil Bio narrows Q3 2026 net loss to $4.23M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Instil Bio, Inc. (TIL) reported a third-quarter 2026 net loss of $4.231 million, compared with $13.587 million in the third quarter of 2025, as corrected. For the first nine months of 2026, net loss was $13.023 million, compared with $63.495 million for the same 2025 period, as corrected. GAAP net loss per share was $0.62 for the quarter and $1.92 for the nine months; non-GAAP net loss per share was $0.48 and $1.32, respectively.

Instil reported $67.091 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments as of September 30, 2026, and expects this balance to fund its current operating plan through 2027. It intends to establish asset-focused development subsidiaries and develop programs internally or in-license them. Instil said its third-quarter 2026 Form 10-Q corrected prior-period information concerning property taxes at its Tarzana facility, tenant reimbursement presentation and other immaterial errors; the errors were not material to previously issued financial statements, and no prior filing is being amended.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointQuarterly GAAP net loss narrowed to $4.231 million from $13.587 million.

Negative

  • None.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash, cash equivalents, restricted cash, marketable securities and long-term investments $67.091 million As of September 30, 2026
Net loss $4.231 million Three months ended September 30, 2026; compared with $13.587 million for the same 2025 period, as corrected
Net loss $13.023 million Nine months ended September 30, 2026; compared with $63.495 million for the same 2025 period, as corrected
GAAP net loss per share $0.62 Three months ended September 30, 2026; compared with $2.01 for the same 2025 period, as corrected
GAAP net loss per share $1.92 Nine months ended September 30, 2026; compared with $9.58 for the same 2025 period, as corrected
Non-GAAP net loss per share $0.48 Three months ended September 30, 2026; compared with $1.75 for the same 2025 period, as corrected
Non-GAAP net loss per share $1.32 Nine months ended September 30, 2026; compared with $6.00 for the same 2025 period, as corrected
Non-GAAP net loss financial
"non-GAAP net loss and non-GAAP net loss per share"
Non-GAAP net loss is a company’s reported loss that has been adjusted by removing certain costs or one-time items that the company believes hide its core operating performance. Think of it like looking at a household budget but excluding an unusual repair or sale; it can show a clearer view of everyday results, which helps investors judge ongoing profitability, but it can also omit real expenses so it should be compared with the standard GAAP loss.
Non-cash stock-based compensation expense financial
"excluding non-cash stock-based compensation expense"
An accounting charge that records the value of shares or stock options a company grants to employees and service providers instead of paying cash; it spreads that non-cash cost over the vesting period so it shows up on the income statement. It matters to investors because, like paying wages with slices of a pie rather than cash, it preserves cash but increases the number of shares outstanding and reduces earnings per share, so investors use it to judge true cash generation and ownership dilution.
Restructuring and impairment charges, net financial
"excluding ... restructuring and impairment charges, net"
Marketable securities financial
"cash, cash equivalents, restricted cash, marketable securities and long-term investments"
Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.
Net loss, three months ended September 30, 2026 $4.231 million Compared with a $13.587 million loss for the same 2025 period, as corrected
Net loss, nine months ended September 30, 2026 $13.023 million Compared with a $63.495 million loss for the same 2025 period, as corrected
GAAP net loss per share, three months ended September 30, 2026 $0.62 Compared with $2.01 for the same 2025 period, as corrected
GAAP net loss per share, nine months ended September 30, 2026 $1.92 Compared with $9.58 for the same 2025 period, as corrected
Non-GAAP net loss per share, three months ended September 30, 2026 $0.48 Compared with $1.75 for the same 2025 period, as corrected
Non-GAAP net loss per share, nine months ended September 30, 2026 $1.32 Compared with $6.00 for the same 2025 period, as corrected
Guidance

Instil expects its cash, cash equivalents, restricted cash, marketable securities and long-term investments as of September 30, 2026, to fund its current operating plan through 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was TIL's net loss in the third quarter of 2026?

Instil reported a $4.231 million net loss for the three months ended September 30, 2026, compared with a $13.587 million net loss for the same period in 2025, as corrected.

How long does Instil expect its cash to fund operations?

Instil expects its cash, cash equivalents, restricted cash, marketable securities and long-term investments as of September 30, 2026, to fund its current operating plan through 2027.

What did Instil say about corrections to its prior-period financial information?

Instil said it identified errors involving property taxes on its Tarzana, California facility, the presentation of amounts reimbursed by the facility's tenant, and certain other immaterial errors. It said the errors were not material to previously issued financial statements; its third-quarter 2026 Form 10-Q corrected prior-period information, and no prior filing is being amended.

How does Instil define non-GAAP net loss?

Instil defines non-GAAP net loss as net loss excluding non-cash stock-based compensation expense and restructuring and impairment charges, net. It says these measures are additional to, not a substitute for or superior to, GAAP measures, and may not be comparable with measures used by other companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
FALSE000178976900017897692026-11-162026-11-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2026
Instil Bio, Inc.
(Exact name of registrant as specified in its Charter)
 
Delaware
001-40215
83-2072195
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
3963 Maple Avenue, Suite 350
Dallas, Texas
75219
(Address of Principal Executive Offices)
(Zip Code)
(972) 499-3350
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.000001 par value
TIL
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).



Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  

Item 2.02 Results of Operations and Financial Condition.

On November 16, 2026, Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2026 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit No.
Description
99.1
Press release, dated November 16, 2026
104
The cover page of this report has been formatted in Inline XBRL.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Instil Bio, Inc.
Dated: November 16, 2026
By:
/s/ Sandeep Laumas, M.D.
Sandeep Laumas, M.D.
Chief Financial Officer and Chief Business Officer
(Principal Financial Officer and Principal Accounting Officer)

image.jpg
Instil Bio Reports Third Quarter 2026 Financial Results and
Provides Corporate Update
DALLAS, TX, November 16, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs, today reported its third quarter 2026 financial results and provided a corporate update.

Recent Highlights:
•Asset-Focused Development Model: By combining focused and experienced teams with strategic support from Instil, Instil intends to establish a portfolio of asset-focused development subsidiaries. To accomplish this strategy, Instil intends to internally develop or in-license programs, building a diversified portfolio of development candidates.
•Cash Position: Cash, cash equivalents, restricted cash, marketable securities and long-term investments totaled approximately $67.1 million as of September 30, 2026, which Instil expects will fund its current operating plan through 2027.

Third Quarter 2026 Financial and Operating Results:
As of September 30, 2026, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $67.1 million, which consisted of $2.5 million in cash and cash equivalents, $0.4 million in restricted cash, $59.5 million in marketable securities and $4.6 million in long-term investments, compared to $76.3 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, consisting of $6.6 million in cash and cash equivalents, $0.2 million in restricted cash and $69.5 million in marketable securities. Instil expects that its cash, cash equivalents, restricted cash, marketable securities and long-term investments as of September 30, 2026 will enable it to fund its operating plan through 2027.
In-process research and development expenses were nil for the three and nine months ended September 30, 2026, compared to nil and $10.0 million for the three and nine months ended September 30, 2025, respectively.
Research and development expenses were $0.2 million and $1.2 million for the three and nine months ended September 30, 2026, respectively, compared to $9.1 million and $21.2 million for the three and nine months ended September 30, 2025, respectively.
General and administrative expenses were $5.8 million and $17.5 million for the three and nine months ended September 30, 2026, respectively, compared to $6.3 million and $22.7 million, as corrected, for the three and nine months ended September 30, 2025, respectively.
Restructuring and impairment charges, net were a reversal of costs of $0.1 million and a charge of $1.1 million for the three and nine months ended September 30, 2026, respectively, compared to nil and $16.6 million for the three and nine months ended September 30, 2025, respectively.

Net loss was $4.2 million and $13.0 million for the three and nine months ended September 30, 2026, respectively, compared to $13.6 million and $63.5 million, as corrected, for the three and nine months ended September 30, 2025, respectively. Net loss per share, basic and diluted, was $0.62 and $1.92 for


image.jpg
the three and nine months ended September 30, 2026, respectively, compared to $2.01 and $9.58, as corrected, for the three and nine months ended September 30, 2025, respectively. Non-GAAP net loss per share, basic and diluted, was $0.48 and $1.32 for the three and nine months ended September 30, 2026, respectively, compared to $1.75 and $6.00, as corrected, for the three and nine months ended September 30, 2025, respectively; see the reconciliation of GAAP to non-GAAP measures below.
In preparing its third-quarter 2026 financial statements, Instil identified errors in previously issued financial statements relating to property taxes on its Tarzana, California facility and the presentation of amounts reimbursed by the facility’s tenant, as well as certain other immaterial errors. The errors were not material to any previously issued financial statements, and no prior filing is being amended. Instil has corrected the prior-period information in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and the 2025 amounts in this release are presented as corrected.

Note Regarding Use of Non-GAAP Financial Measures
In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges, net. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil’s operating results. In addition, these non-GAAP financial measures are among the indicators Instil’s management uses for planning purposes and to measure Instil’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.

About Instil Bio
Instil Bio, Inc. is a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs. For more information, visit www.instilbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “exploring,” “evaluating,” “focused,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “targets,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements concerning Instil’s expectations regarding establishing a portfolio of asset-focused development subsidiaries, internally developing or in-licensing programs, and building a diversified portfolio of development candidates; Instil’s expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties related to pursuing potential transactions to acquire companies or equity interests therein or in-license product candidates, and the sufficiency of Instil’s cash resources, as well as interest rates, inflation and other


image.jpg
macroeconomic factors which could materially and adversely affect Instil’s business and operations, and other risks and uncertainties affecting Instil’s plans and strategy, including those discussed in the section titled “Risk Factors” in Instil’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the SEC and Instil ’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 27, 2026, as well as Instil’s other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.

Contacts:
Investor Relations:
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com

Media Relations:
Kimberly Ha
KKH Advisors
1-917-291-5744
kimberly.ha@kkhadvisors.com


image.jpg
INSTIL BIO, INC.
SELECTED FINANCIAL DATA

Selected Condensed Consolidated Balance Sheet Data
(Unaudited; in thousands)
September 30, 2026December 31, 2025
Cash, cash equivalents, restricted cash, marketable securities and long-term investments$67,091 $76,295 
Total assets$195,645 $204,515 
Total liabilities$93,081 $91,844 
Total stockholders’ equity$102,564 $112,671 
Condensed Consolidated Statements of Operations
(Unaudited; in thousands, except share and per share amounts)
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
Operating expenses:
In-process research and development$— $— $— $10,000 
Research and development233 9,127 1,172 21,241 
General and administrative5,833 6,344 17,510 22,689 
Restructuring and impairment charges, net(81)— 1,092 16,622 
Total operating expenses5,985 15,471 19,774 70,552 
Loss from operations(5,985)(15,471)(19,774)(70,552)
Interest income615 893 1,925 3,112 
Interest expense(1,554)(1,582)(4,688)(4,398)
Other rental income2,697 2,691 8,090 8,076 
Gain on contract termination— — 1,620 — 
Other (expense) income, net(4)(118)(196)267 
Net loss$(4,231)$(13,587)$(13,023)$(63,495)
Net loss per share, basic and diluted$(0.62)$(2.01)$(1.92)$(9.58)
Weighted-average shares used in computing net loss per share, basic and diluted6,781,976 6,757,742 6,781,976 6,629,949 






image.jpg
INSTIL BIO, INC.
Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss per Share
(Unaudited; in thousands, except share and per share amounts)
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
Net loss$(4,231)$(13,587)$(13,023)$(63,495)
Adjustments:
Non-cash stock-based compensation expense984 1,768 3,005 7,087 
Restructuring and impairment charges, net(81)— 1,092 16,622 
Non-GAAP net loss$(3,328)$(11,819)$(8,926)$(39,786)
Net loss per share, basic and diluted$(0.62)$(2.01)$(1.92)$(9.58)
Adjustments:
Non-cash stock-based compensation expense per share0.15 0.26 0.44 1.07 
Restructuring and impairment charges, net per share (0.01)— 0.16 2.51 
Non-GAAP net loss per share, basic and diluted*$(0.48)$(1.75)$(1.32)$(6.00)
Weighted-average shares outstanding, basic and diluted6,781,976 6,757,742 6,781,976 6,629,949 
* Non-GAAP net loss per share, basic and diluted may not total due to rounding.



###

Filing Exhibits & Attachments

4 documents

Keep reading